Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,659 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Schizophrenia; Psychosis Clear all
Active, not recruiting Not applicable Interventional

Youth Nominated Support Team

NCT05558332
View directory record Official record
Conditions
Psychosis, Suicide, Health Care Utilization, Family Members
Interventions
Youth-Nominated Support Teams for CHR
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
12 Years to 25 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Withdrawn Phase 1 Interventional

Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder

NCT00892021
View directory record Official record
Conditions
Schizophrenia
Interventions
NSA-789, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 16, 2026, 6:29 AM EDT
Recruiting Phase 3 Interventional

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

NCT06229210
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autism Spectrum Disorder
Interventions
Lumateperone
Drug
Lead sponsor
Intra-Cellular Therapies, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
59
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 4 Interventional

Cognitive Skills Training Using Computer for Patients With Severe Mental Illness

NCT01036282
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Computerized Cognitive Skill Training, CRT and Social Cognition
Behavioral
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

NCT01082250
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2011 · Synced Oct 16, 2026, 6:29 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers

NCT00001246
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Schizophrenia, Attention Deficit Disorder With Hyperactivity
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
3 Years to 120 Years
Enrollment
4,274 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1990
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed No phase listed Observational

Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

NCT01364818
View directory record Official record
Conditions
Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 4 Interventional Results available

A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder

NCT00621777
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
Interventions
Varenicline, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
10
States / cities
Birmingham, Alabama • Bloomington, Indiana • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 16, 2026, 6:29 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Schizoaffective Disorder Using Mifepristone

NCT00725270
View directory record Official record
Conditions
Psychotic Disorders, Depressive Disorder, Major, Depressive Disorder
Interventions
Mifepristone, Placebo Oral Tablet
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 16, 2026, 6:29 AM EDT
Not yet recruiting Not applicable Interventional

NST-SPARK Open-Label Phase 1 STTR (IGNITE)

NCT07593456
View directory record Official record
Conditions
Schizophrenia / Schizoaffective Disorder
Interventions
NST-SPARK
Device
Lead sponsor
North Shore Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
2
States / cities
Glen Oaks, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 16, 2026, 6:29 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Functions Underlying Visuospatial Attention Deficits in Schizophrenia

NCT01399437
View directory record Official record
Conditions
Schizophrenia
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 1Phase 2 Interventional

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

NCT00089869
View directory record Official record
Conditions
Schizophrenia
Interventions
olanzapine, atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Cerritos, California • Chula Vista, California • Garden Grove, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2006 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability Study of Drug to Treat Schizophrenia

NCT00044005
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 20 mg, Lurasidone 40 mg, Lurasidone 80mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
26
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Bupropion on Smoking Behavior in Smokers With Schizophrenia

NCT00218231
View directory record Official record
Conditions
Schizophrenia, Tobacco Use Disorder
Interventions
300 mg/day bupropion-sr, 0 mg/day bupropion-sr
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Not applicable Interventional

Integrated Coping and Awareness Training

NCT02400502
View directory record Official record
Conditions
Schizophrenia
Interventions
I-CAT Therapy
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 16, 2026, 6:29 AM EDT
Recruiting Phase 4 Interventional

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637
View directory record Official record
Conditions
Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
Not listed
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 16, 2026, 6:29 AM EDT
Terminated Phase 1 Interventional

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

NCT01568203
View directory record Official record
Conditions
Schizophrenia
Interventions
AMG 579, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 16, 2026, 6:29 AM EDT
Not listed Phase 1 Interventional

Tocilizumab in Schizophrenia

NCT02874573
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Tocilizumab, Normal saline
Drug
Lead sponsor
Brian Miller
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2023 · Synced Oct 16, 2026, 6:29 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)

NCT00211380
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
aripiprazole
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 2Phase 3 Interventional

Galantamine for Cognitive Deficits in Schizophrenia

NCT00463879
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 1 Interventional

A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

NCT01940159
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Not applicable Interventional Results available

Minnesota Community-Based Cognitive Training in Early Psychosis

NCT03079024
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder, Schizophreniform Disorders, Psychosis NOS, Depression Psychotic Feature, Bipolar Disorder With Psychotic Features, Unspecified Psychosis
Interventions
Targeted Cognitive Training, General Cognitive Exercises, Coordinated Specialty Care for First Episode Psychosis
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Phase 4 Interventional

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

NCT00177580
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Pravastatin
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 16, 2026, 6:29 AM EDT
Completed Not applicable Interventional Results available

Theta Burst Stimulation for Schizophrenia

NCT03288779
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Theta Burst Stimulation
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Oct 16, 2026, 6:29 AM EDT